Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency

NCT00646542 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

525

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Vildagliptin
DRUG: Placebo

Sponsor

Novartis